Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07457229) titled 'Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: GRIN Therapeutics, Inc.
Condition:
Hepatic Impairment
Intervention:
Drug: Radiprodil
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: March 3, 2026
Target Sample Size: 40
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT074572...